TG Therapeutics' strong cash position and Briumvi success fuel growth potential. Find out why TGTX stock is rated a strong ...

TG Therapeutics' financial health is solid, with a market cap of $5.7bn and a strong cash position, ensuring an indefinite ...

周一，TG Therapeutics（NASDAQ:TGTX）股价在Cantor Fitzgerald重申增持评级后大幅上涨。这家专注于开发B细胞介导疾病治疗方案的生物制药公司股价上涨超过18%，与XBI生物科技指数1%的跌幅形成鲜明对比。目前该股交易价格为$35.43，接近其52周高点$36.84，过去一年收益率达到67.5%。根据 InvestingPro ...

生物技术公司 TG Therapeutics（TGTX） 股票在公布超出预期的第四财季业绩后，成为投资者追捧的热门对象。根据标普全球市场情报汇编的数据，截至周五（3月7日）下午，该公司的股价自本周以来已上涨近27%。

TG Therapeutics (TGTX) stock surged 17% on Mar. 3 after the company reported revenue that topped Wall Street estimates. The ...

Biotech stock TG Therapeutics is outperforming the major indexes in a declining stock market. TGTX stock hit a new high on ...

TG Therapeutics, Inc. has announced its schedule for presenting data on BRIUMVI® (ublituximab-xiiy) at the upcoming American Academy of Neurology 2025 annual meeting in San Diego, California ...

Investing.com -- TG Therapeutics（纳斯达克代码：TGTX）发布强劲的第四季度财报后，股价上涨14%。该生物制药公司公布的截至2024年12月31日的第四季度和全年财务业绩显示，每股收益为正值，收入大幅增长。

TG Therapeutics (NasdaqCM:TGTX) saw its share price surge by 28% last week following a robust earnings announcement. The company's fourth-quarter revenue grew by 146% year-over-year, accompanied by a ...

Fourth quarter and full year 2024 BRIUMVI U.S. net revenue of $103.6 million and $310 million, respectivelyTarget guidance of approximately $540 ...

The FDA has approved the company’s BRIUMVI for treating relapsing forms of multiple sclerosis in adults, including clinically isolated syndrome, relapsing-remitting disease, and active secondary ...

Michael S. Weiss, the Company's Chairman and Chief Executive Officer, stated, “2024 was a year of significant outperformance and growth for TG, highlighted by the strong adoption of BRIUMVI for adult ...